Physician profile
Anthony D Browning
NPI 1255588737
$31,760.79
in general payments reported to CMS, 2019-2025
15 companies · $8,176 in 2025
The $8,176 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $7,674 · 2023: $9,630 · 2024: $5,764 · 2025: $8,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $2,990 · Food and Beverage: $1,666 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,887.50 |
| Travel and Lodging | $2,990.32 |
| Food and Beverage | $1,665.70 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,212.83 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $468.24 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $396.07 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.88 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $134.86 | 2023-2024 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $99.34 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $67.97 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $59.43 | 2021 | |
| Lundbeck LLC | $55.57 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $34.39 | 2021 | |
| Alfasigma USA, INC. | $17.59 | 2021 | |
| Allergan, INC. | $14.02 | 2021 | |
| Alkermes, INC. | $11.27 | 2021 | |
| Eisai INC. | $11.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.